To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension

• Status: Recruiting
• Trial end date: 2023-03-31
• Target enrollment: 0
• Participant gender: All

Summary

A Multi-center, Randomized, Double-blind, Parallel, phase III Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0101+C2101 in Patients with Dyslipidemia and Hypertension.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: JW Pharmaceutical

Criteria

Inclusion Criteria:

• Patients with hypertension and dyslipidemia

Exclusion Criteria:

• The subject not meet the specified msBP and LDL-C level